Each relationship is unique, but generally the alliances include a joint steering committee that meets regularly, dedicated project managers on both sides, a contractual framework that results in no contract or budget negotiations for 3-5 years and substantial financial and resource commitments.
Additionally, some of the alliances may contain a risk-sharing component.
The immunotherapy platform at The University of Texas MD Anderson Cancer Center and the global biopharmaceutical company AbbVie will join forces to find new ways to unleash the immune system’s potential to fight cancer.
Collaboration to develop therapeutic antibodies.
View press release (Dec. 8,2015)
Agreement to develop a new treatment for patients with acute myeloid leukemia.
View press release (April 3, 2015)
Studies with AstraZeneca target gynecologic cancers.
View press release (Jan. 30, 2015)
MD Anderson’s Neurodegeneration Consortium collaborates with Axxam to identify and develop novel small molecule modulators of an undisclosed G-protein coupled receptor linked to Alzheimer’s disease.
View press release (Dec. 4, 2015)
MD Anderson and Boehringer Ingelheim team up to develop innovative medicines for pancreatic ductal adenocarcinoma.
View press release (Dec. 2, 2015)
MD Anderson and Cellectis announce CAR T-cell preclinical and clinical strategic alliance.
View press release (Sept. 3, 2015)
Strategic collaboration to develop exosomes as a new therapeutic and diagnostic modality.
View press release (Nov. 17, 2015)
Cytomx and MD Anderson collaborate to research PRoCAR-NK cell therapies.
View press release,(Nov. 5, 2015)
Scientists from Enumeral and MD Anderson will collaborate on the discovery and development of novel monoclonal antibodies against specified targets in immuno-oncology.
View press release (Jan. 1, 2016)
MD Anderson, Foundation Medicine team up to improve targeted therapies in metastatic disease.
View press release (Aug. 14, 2014)
Helsinn Healthcare SA
Strategic alliance in cancer supportive and palliative care.
View press release (April 26, 2016)
Alliance to develop non-viral adoptive cellular cancer immunotherapies.
View press release (Jan. 13, 2015)
MD Anderson Announces Collaboration with Johnson & Johnson Innovation on cancer immunotherapy (Janssen is an affiliate of Johnson & Johnson Innovation)
View press release (Jan. 21, 2014)
Janssen, Johnson & Johnson Innovation
MD Anderson Announces Collaboration with Johnson & Johnson Innovation on cancer immunotherapy. (Janssen is an affiliate of Johnson & Johnson Innovation)
View press release (Jan. 21, 2014)
Strategic pre-clinical and clinical collaboration that will include development of KA2237 and KA2507.
View press release (Dec. 10, 2015)
Kymab and MD Anderson announce a strategic cancer drug discovery and development alliance.
View press release (Jan. 7, 2016)
MD Anderson announces that they have entered into a strategic collaboration with Merck to evaluate Merck’s anti-PD-1 therapy in combination with other treatments.
View press release (August 13, 2015)
Collaboration to translate small molecules with anti cancer activity into clinical therapies.
MD Anderson and NanoString Technologies Announce Multi-Year Collaboration
View press release (April 1, 2015)
Nektar Therapeutics and MD Anderson announce a research collaboration that includes a Phase 1/2 clinical study to evaluate NKTR-214.
View press release (June 2, 2015)
Oncoceutics and MD Anderson team up on novel drug.
View press release (Jan. 5, 2015)
Oncora Medical, Inc.
View press release (April 2017)
OncoResponse and MD Anderson collaborate to identify therapeutic antibodies against novel targets from immuno-oncology treated patients.
View press release (Oct. 6, 2015)
Collaboration to discover and develop small molecule product candidates against undisclosed immuno-oncology targets.
View press release (March 29, 2016)
Strategic collaboration to identify and develop novel cancer agents to multiple targets.
View press release (Jan. 6, 2016)